ChromaDex (CDXC) Receives FDA GRAS No Objection Letter for NIAGEN
- Stocks hit by tech slide; yen flails at intervention zone
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen hits fresh 34-year lows against dollar ahead of BOJ meeting
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
ChromaDex (CDXC) Reports Q2 EPS of $0.00
August 11, 2016 4:41 PM EDTChromaDex (NASDAQ: CDXC) reported Q2 EPS of $0.00, versus ($0.01) reported last year. Revenue for the quarter came in at $8.8 million, versus $6.1 million reported last year.
For earnings history and earnings-related data on ChromaDex (CDXC) click here.
... More